Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2785

1.

Gestational and early postnatal hypothyroidism alters VGluT1 and VGAT bouton distribution in the neocortex and hippocampus, and behavior in rats.

Navarro D, Alvarado M, Navarrete F, Giner M, Obregon MJ, Manzanares J, Berbel P.

Front Neuroanat. 2015 Feb 17;9:9. eCollection 2015.

PMID:
25741243
[PubMed - as supplied by publisher]
2.

Decoupling of N-acetyl-aspartate and Glutamate within the Dorsolateral Prefrontal Cortex in Schizophrenia.

Coughlin JM, Tanaka T, Marsman A, Wang H, Bonekamp S, Kim PK, Higgs C, Varvaris M, Edden RA, Pomper M, Schretlen D, Barker PB, Sawa A.

Curr Mol Med. 2015 Mar 2. [Epub ahead of print]

PMID:
25732147
[PubMed - as supplied by publisher]
3.

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Li ML, Hu XQ, Li F, Gao WJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Feb 24;60C:66-76. doi: 10.1016/j.pnpbp.2015.02.012. [Epub ahead of print] Review.

PMID:
25724760
[PubMed - as supplied by publisher]
4.

Antineuronal Antibodies Against Neurotransmitter Receptors and Synaptic Proteins in Schizophrenia: Current Knowledge and Clinical Implications.

Steiner J, Schiltz K, Bernstein HG, Bogerts B.

CNS Drugs. 2015 Feb 28. [Epub ahead of print]

PMID:
25724386
[PubMed - as supplied by publisher]
5.

Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

Javitt DC.

Ann N Y Acad Sci. 2015 Feb 26. doi: 10.1111/nyas.12689. [Epub ahead of print]

PMID:
25721890
[PubMed - as supplied by publisher]
6.

Drug development in schizophrenia: are glutamatergic targets still worth aiming at?

Goff DC.

Curr Opin Psychiatry. 2015 Feb 23. [Epub ahead of print]

PMID:
25710242
[PubMed - as supplied by publisher]
7.

Dysbindin (DTNBP1) variants are associated with hallucinations in schizophrenia.

Cheah SY, Lawford BR, Young RM, Morris CP, Voisey J.

Eur Psychiatry. 2015 Feb 16. pii: S0924-9338(15)00052-8. doi: 10.1016/j.eurpsy.2015.01.008. [Epub ahead of print]

PMID:
25697573
[PubMed - as supplied by publisher]
8.

Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor.

Lavreysen H, Ahnaou A, Drinkenburg W, Langlois X, Mackie C, Pype S, Lütjens R, Le Poul E, Trabanco AA, Nuñez JM.

Pharmacol Res Perspect. 2015 Feb;3(1):e00096. doi: 10.1002/prp2.96. Epub 2014 Dec 9.

PMID:
25692015
[PubMed]
Free PMC Article
9.

A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice.

Errico F, D'Argenio V, Sforazzini F, Iasevoli F, Squillace M, Guerri G, Napolitano F, Angrisano T, Di Maio A, Keller S, Vitucci D, Galbusera A, Chiariotti L, Bertolino A, de Bartolomeis A, Salvatore F, Gozzi A, Usiello A.

Transl Psychiatry. 2015 Feb 17;5:e512. doi: 10.1038/tp.2015.2.

PMID:
25689573
[PubMed - in process]
10.

Frontal P3 event-related potential is related to brain glutamine/glutamate ratio measured in vivo.

Hall MH, Jensen JE, Du F, Smoller JW, O'Connor L, Spencer KM, Öngür D.

Neuroimage. 2015 Feb 14;111C:186-191. doi: 10.1016/j.neuroimage.2015.02.014. [Epub ahead of print]

PMID:
25687595
[PubMed - as supplied by publisher]
11.

Deconstructing N-methyl-d-aspartate glutamate receptor contributions to cortical circuit functions to construct better hypotheses about the pathophysiology of schizophrenia.

Krystal JH.

Biol Psychiatry. 2015 Mar 15;77(6):508-10. doi: 10.1016/j.biopsych.2014.10.010. No abstract available.

PMID:
25687430
[PubMed - in process]
12.

Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-Guerrero A.

Schizophr Res. 2015 Feb 12. pii: S0920-9964(15)00073-0. doi: 10.1016/j.schres.2015.01.043. [Epub ahead of print] Review.

PMID:
25684554
[PubMed - as supplied by publisher]
13.

Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).

Martín-Martín ML, Bartolomé-Nebreda JM, Conde-Ceide S, Alonso de Diego SA, López S, Martínez-Viturro CM, Tong HM, Lavreysen H, Macdonald GJ, Steckler T, Mackie C, Bridges TM, Daniels JS, Niswender CM, Noetzel MJ, Jones CK, Conn PJ, Lindsley CW, Stauffer SR.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1310-7. doi: 10.1016/j.bmcl.2015.01.038. Epub 2015 Jan 28.

PMID:
25683622
[PubMed - in process]
14.

The effect of ketamine on configural facial processing.

MBSc EN, Joshua N, Morgan C, Rossell SL.

J Clin Psychopharmacol. 2015 Apr;35(2):188-91. doi: 10.1097/JCP.0000000000000278.

PMID:
25679135
[PubMed - in process]
15.

Synthesis and biological evaluation of aryl isoxazole derivatives as metabotropic glutamate receptor 1 antagonists: A potential treatment for neuropathic pain.

Cho GH, Kim T, Son WS, Seo SH, Min SJ, Cho YS, Keum G, Jeong KS, Koh HY, Lee J, Pae AN.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1324-8. doi: 10.1016/j.bmcl.2015.01.035. Epub 2015 Jan 24.

PMID:
25677662
[PubMed - in process]
16.

Amino acids inhibit kynurenic acid formation via suppression of kynurenine uptake or kynurenic acid synthesis in rat brain in vitro.

Sekine A, Okamoto M, Kanatani Y, Sano M, Shibata K, Fukuwatari T.

Springerplus. 2015 Feb 1;4:48. doi: 10.1186/s40064-015-0826-9. eCollection 2015.

PMID:
25674503
[PubMed]
Free PMC Article
17.

Environmental Enrichment Ameliorates Behavioral Impairments Modeling Schizophrenia in Mice Lacking Metabotropic Glutamate Receptor 5.

Burrows EL, McOmish CE, Buret LS, Van den Buuse M, Hannan AJ.

Neuropsychopharmacology. 2015 Feb 10. doi: 10.1038/npp.2015.44. [Epub ahead of print]

PMID:
25666312
[PubMed - as supplied by publisher]
18.

Nicotinic receptors and attention.

Hahn B.

Curr Top Behav Neurosci. 2015;23:103-35. doi: 10.1007/978-3-319-13665-3_5.

PMID:
25655889
[PubMed - in process]
19.

S-SCAM, A Rare Copy Number Variation Gene, Induces Schizophrenia-Related Endophenotypes in Transgenic Mouse Model.

Zhang N, Zhong P, Shin SM, Metallo J, Danielson E, Olsen CM, Liu QS, Lee SH.

J Neurosci. 2015 Feb 4;35(5):1892-904. doi: 10.1523/JNEUROSCI.3658-14.2015.

PMID:
25653350
[PubMed - in process]
20.

Striatal dopamine release in a schizophrenia mouse model measured by electrochemical amperometry in vivo.

Xu H, Zuo P, Wang S, Zhou L, Sun X, Hu M, Liu B, Wu Q, Dou H, Liu B, Zhu F, Teng S, Zhang X, Wang L, Li Q, Jin M, Kang X, Xiong W, Wang C, Zhou Z.

Analyst. 2015 Feb 5. [Epub ahead of print]

PMID:
25651802
[PubMed - as supplied by publisher]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk